NEWARK, N.J. (CN) - Seeking to monopolize the treatment market for heroin and opioid addiction, Reckitt Benckiser Pharmaceuticals, now known as Indivior, are blocking drugmakers from introducing a generic version of Suboxone, a competitor claims in a federal complaint.
The drug's active ingredients, buprenorphine and naloxone, are also known as Bu-Na.
Categories / Uncategorized
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.